BACKGROUND: Botswana has the most comprehensive public program in Africa for providing antiretroviral therapy to treat HIV and prevent mother-to-child transmission (PMTCT). Botswana guidelines prioritize CD4(+) cell count testing during pregnancy and initiation of highly active antiretroviral treatment (HAART) for women who qualify for treatment. We analyzed rates of HIV testing, CD4 cell count testing, and HAART initiation during pregnancy. METHODS: From October 2007 through June 2008, we reviewed obstetric and laboratory records of women at Princess Marina Hospital in Gaborone, Botswana. RESULTS: We recorded information from 3056 women. Of 2675 women eligible for the PMTCT program, 2623 (98%) had a documented HIV status, of whom 793 (30%) were HIV infected. Among women who were treatment naive at pregnancy conception, 397 (59%) had recorded CD4(+) cell counts, of whom 62 (16%) had a CD4(+) cell count <200 cells per cubic millimeter. Among this subset, 23 (37%) initiated HAART during pregnancy, 26 (42%) received zidovudine prophylaxis, and 13 (21%) received no therapy. CONCLUSIONS: We observed low rates of CD4(+) cell count testing and HAART initiation during pregnancy. Antenatal clinics should prioritize CD4(+) cell count testing and referral of women who qualify for HAART to maximize benefits of maternal treatment and PMTCT.
BACKGROUND: Botswana has the most comprehensive public program in Africa for providing antiretroviral therapy to treat HIV and prevent mother-to-child transmission (PMTCT). Botswana guidelines prioritize CD4(+) cell count testing during pregnancy and initiation of highly active antiretroviral treatment (HAART) for women who qualify for treatment. We analyzed rates of HIV testing, CD4 cell count testing, and HAART initiation during pregnancy. METHODS: From October 2007 through June 2008, we reviewed obstetric and laboratory records of women at Princess Marina Hospital in Gaborone, Botswana. RESULTS: We recorded information from 3056 women. Of 2675 women eligible for the PMTCT program, 2623 (98%) had a documented HIV status, of whom 793 (30%) were HIV infected. Among women who were treatment naive at pregnancy conception, 397 (59%) had recorded CD4(+) cell counts, of whom 62 (16%) had a CD4(+) cell count <200 cells per cubic millimeter. Among this subset, 23 (37%) initiated HAART during pregnancy, 26 (42%) received zidovudine prophylaxis, and 13 (21%) received no therapy. CONCLUSIONS: We observed low rates of CD4(+) cell count testing and HAART initiation during pregnancy. Antenatal clinics should prioritize CD4(+) cell count testing and referral of women who qualify for HAART to maximize benefits of maternal treatment and PMTCT.
Authors: Scott Dryden-Peterson; Oluwemimo Jayeoba; Michael D Hughes; Haruna Jibril; Koona Keapoletswe; Josephine Tlale; Taolo A Modise; Aida Asmelash; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; Max Essex; Roger L Shapiro; Shahin Lockman Journal: J Acquir Immune Defic Syndr Date: 2011-11-01 Impact factor: 3.731
Authors: Amitabh B Suthar; David Hoos; Alba Beqiri; Karl Lorenz-Dehne; Craig McClure; Chris Duncombe Journal: Bull World Health Organ Date: 2012-11-28 Impact factor: 9.408
Authors: Maria H Kim; Saeed Ahmed; Geoffrey A Preidis; Elaine J Abrams; Mina C Hosseinipour; Thomas P Giordano; Elizabeth Y Chiao; Mary E Paul; Avni Bhalakia; Debora Nanthuru; Peter N Kazembe Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240
Authors: Scott Dryden-Peterson; Kara Bennett; Michael D Hughes; Adrian Veres; Oaitse John; Rosina Pradhananga; Matthew Boyer; Carolyn Brown; Bright Sakyi; Erik van Widenfelt; Koona Keapoletswe; Madisa Mine; Sikhulile Moyo; Aida Asmelash; Mark Siedner; Mompati Mmalane; Roger L Shapiro; Shahin Lockman Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: Ohemaa B Poku; Ari R Ho-Foster; Patlo Entaile; Supriya Misra; Haitisha Mehta; Shathani Rampa; Melody Goodman; Tonya Arscott-Mills; Evan Eschliman; Valerie Jackson; Tadele Melese; Timothy D Becker; Marlene Eisenberg; Bruce Link; Vivian Go; Philip Renison Opondo; Michael B Blank; Lawrence H Yang Journal: Trials Date: 2020-10-07 Impact factor: 2.279
Authors: Laura Ferguson; Alison D Grant; James Lewis; Karina Kielmann; Deborah Watson-Jones; Sophie Vusha; John O Ong'ech; David A Ross Journal: PLoS One Date: 2014-03-19 Impact factor: 3.240